ZTS
Zoetis Inc.
NYSE · USHealthcareDrug Manufacturers - Specialty & Generic
$76.19-0.48%
Price as of Jul 20, 2026
ZTS growth
Zoetis Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +2.4%
- EBITDA
- +2.7%
- EBIT
- +4.0%
- EPS
- +8.2%
- Free cash flow
- -6.4%
- Operating cash flow
- -7.7%
Forward estimates
- Revenue
- +6.4%
- EBITDA
- +13.5%
- EPS
- +19.6%
Three-year CAGR
- Revenue
- +5.4%
- EBITDA
- +6.6%
- EBIT
- +7.1%
- Net income
- +8.1%
- EPS
- +10.2%
- Free cash flow
- +19.9%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.